DEXTENZA is a corticosteroid intracanalicular insert placed through the punctum, a natural opening in the eye lid, into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives. Following treatment, DEXTENZA is intended to resorb and exit the nasolacrimal system without the need for removal.
DEXTENZA has completed Phase 3 evaluation for the treatment of ocular pain and inflammation following ophthalmic surgery. DEXTENZA is also being studied for allergic conjunctivitis.
A New Drug Application (NDA) Submission for DEXTENZA was accepted by the FDA for the treatment of ocular pain following ophthalmic surgery.
Caution: NEW DRUG – DEXTENZA is currently undergoing clinical evaluation in the United States and is limited by United States law to investigational use only. This product has not been approved by the FDA as safe or effective.
The hydrogel technology is designed to release a tapered dose of dexamethasone for up to 30 days, with a single insertion. 1,2
¹Walters T, Bafna S, Vold S, et al. Efficacy and safety of sustained release dexamethasone for the treatment of ocular pain and inflammation after cataract surgery: results from two phase 3 studies. J Clin Exp Ophthalmol. 2016;7(4):1-11.
²Blizzard C, Desai A, Driscoll A. Pharmacokinetic studies of sustained-release depot for dexamethasone in beagle dogs. J Ocul Pharmacol Ther. 2016;32(9):595-600.